• Patchless Transdermal Drug Delivery ... - Ecn5.com ecn5

14
MARCH 2011 • TransDermal
coworkers applied a phage library to rat skin and
then collected phages that were isolated from the
animal’s blood stream [7]. They were able to isolate a
peptide with the sequence CSSSPSKHC. The re -
searchers synthesized a cyclized analogue of this
peptide and ultimately were able to show improved
insulin delivery.
Conclusion
The methods described in this article have shown that
it is possible to deliver peptides in vivo via transdermal
routes. This article, however, is not a comprehensive
discussion of such formulations. Many other
transdermal approaches are known, including techniques
such as painless microneedles [8].
References
1. Michniak, et al. European Journal of Pharmaceutics and
Biopharmaceutics. 2005, 60:179–191.
2. Raiman J, Koljonen M, Huikko K, Kostiainen R, Hirvonen
J. Delivery and stability of LHRH and Nafarelin in human skin: The
effect of constant/pulsed iontophoresis. Eur. J. Pharm. Sci. 2004,
21:371–377.
3. Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK.
Stability of a transdermal salmon calcitonin formulation. Drug
Deliv. 2003, 10:41–45.
4. Medi BM and Singh J. Electronically facilitated transdermal
delivery of human parathyroid hormone (1-34). Int. J. Pharm.
2003, 263:25–33.
5. Prausnitz, MR and Langer R. Nature Biotechnology. 2008,
26(11):1261-1268.
6. Karande P, Jain A, Mitragotri S. Nature Biotechnology
2004, 22(2):192-197.
7. Chen Y, Shen Y, Guo X, Zhang C, Yang W, Ma M, Liu S,
Zhang M, Wen L. Transdermal protein delivery by a co-administered
peptide identified via phage display. Nature Biotechnology.
2006, 24(4):455-460.
8. Daniel P. Wermeling et al. Proc Natl Acad Sci. USA 102,
4688–4693 (2005).
Xiaorong Shen received her bachelor’s and master’s degrees in biology at
Nanjing University in China and a PhD in genetics at Purdue
University in the USA. Before receiving her PhD, she worked for more
than eight years at the Chinese Jiangsu Institute on preformulations,
formulations, manufacturing processes, analytical methods, and development.
In 2007, she joined Primera Analytical Solutions where she
now heads its formulations group. She works primarily on advanced
material formulations, including bioresorbable polymers, large-molecule
formulations, and stability and compatibility issues with novel, cuttingedge
formulations.
David Jones joined Primera Analytical Solutions in 2007 and currently
is vice president of sales and marketing. With 25 years in the pharmaceutical
industry, he previously was director of pharmaceutical sales for
Isochem and vice president of development at Hopewell Laboratories. In
the past, he worked on the development of a novel class of peptide
reagents, urethane protected N-carboxyanhydrides (UNCAs), for
Professor Murray Goodman’s laboratories and managed a laboratory at
Multiple Peptide Systems that produced the first commercial peptide
libraries. He received his bachelor’s and master’s degrees in chemistry at
the State University of New York at Stony Brook
Contact David Jones at Primera Analytical Solutions, 259 Wall Street,
Princeton NJ 08534; Tel: +1 908 295 9011; E-mail: david.jones
@primera-corp.com. www.primera-corp.com
www.transdermalmag.com